Search our Database of Scientific Publications and Authors

I’m looking for a

    867 results match your criteria Buruli Ulcer

    1 OF 18

    Mycolactone cytotoxicity in Schwann cells could explain nerve damage in Buruli ulcer.
    PLoS Negl Trop Dis 2017 Aug 4;11(8):e0005834. Epub 2017 Aug 4.
    Department of Pathology, Kagoshima University, Kagoshima, Japan.
    Buruli ulcer is a chronic painless skin disease caused by Mycobacterium ulcerans. The local nerve damage induced by M. ulcerans invasion is similar to the nerve damage evoked by the injection of mycolactone in a Buruli ulcer mouse model. Read More

    Bacterial diversity in Buruli ulcer skin lesions: Challenges in the clinical microbiome analysis of a skin disease.
    PLoS One 2017 27;12(7):e0181994. Epub 2017 Jul 27.
    Mycobacteriology unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
    Background: Buruli ulcer (BU) is an infectious disease caused by Mycobacterium ulcerans and considered the third most prevalent mycobacterial disease in humans. Secondary bacterial infections in open BU lesions are the main cause of pain, delayed healing and systemic illness, resulting in prolonged hospital stay. Thus, understanding the diversity of bacteria, termed the microbiome, in these open lesions is important for proper treatment. Read More

    In Silico Prediction of Antibiotic Resistance in Mycobacterium ulcerans Agy99 through Whole Genome Sequence Analysis.
    Am J Trop Med Hyg 2017 Jul 24. Epub 2017 Jul 24.
    Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, UMR CNRS 7278-IRD 198 IHU, Méditerranée Infection, Faculté de Médecine et de Pharmacie, Aix-Marseille Université, Marseille, France.
    Buruli ulcer is an emerging infectious disease caused by Mycobacterium ulcerans that has been reported from 33 countries. Antimicrobial agents either alone or in combination with surgery have been proved to be clinically relevant and therapeutic strategies have been deduced mainly from the empirical experience. The genome sequences of M. Read More

    Hearing thresholds in patients with drug-resistant tuberculosis: baseline audiogram configurations and associations.
    J Bras Pneumol 2017 May-Jun;43(3):195-201
    . Ogun State Tuberculosis, Leprosy and Buruli Ulcer Control Program, Ministry of Health, Ogun State, Nigeria.
    Objective:: To use baseline audiogram parameters in order to ascertain whether drug-resistant tuberculosis (DR-TB) has effects on hearing, as well as to describe the configurations of the audiograms and to determine whether there are parameters that can be associated with those configurations.

    Methods:: This was a prospective study involving patients diagnosed with DR-TB at a tuberculosis treatment center in the state of Ogun, in Nigeria. The patients included in the study were submitted to pure tone audiometry at baseline (within two weeks after treatment initiation). Read More

    Ecohealth research in Africa: where from-where to?
    Acta Trop 2017 Jul 18. Epub 2017 Jul 18.
    Swiss Tropical and Public Health Institute, P.O. Box, CH-4002 Basel, Switzerland; University of Basel, P.O. Box, CH-4003 Basel, Switzerland.
    Epidemiological mapping and risk profiling build on the idea that diseases are tied to social-ecological systems that govern the distribution and abundance of transmissible pathogens, vectors and hosts. This is the heart of the emerging field of ecohealth, which examines how biological, cultural, demographic, economic, physical, political and social environments change can affect the health and wellbeing of humans, animals and ecosystems and the services they provide. This paper is an overview of a special issue of Acta Tropica, whose 15 publications reflect a geographically and epidemiologically diverse landscape of ecohealth in Africa. Read More

    A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone.
    Toxins (Basel) 2017 Jul 18;9(7). Epub 2017 Jul 18.
    Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France.
    Mycolactone, a polyketide molecule produced by Mycobacterium ulcerans, is the etiological agent of Buruli ulcer. This lipid toxin is endowed with pleiotropic effects, presents cytotoxic effects at high doses, and notably plays a pivotal role in host response upon colonization by the bacillus. Most remarkably, mycolactone displays intriguing analgesic capabilities: the toxin suppresses or alleviates the pain of the skin lesions it inflicts. Read More

    Clearance of viable Mycobacterium ulcerans from Buruli ulcer lesions during antibiotic treatment as determined by combined 16S rRNA reverse transcriptase /IS 2404 qPCR assay.
    PLoS Negl Trop Dis 2017 Jul 3;11(7):e0005695. Epub 2017 Jul 3.
    Kwame Nkrumah University of Science and Technology (KNUST), School of Medical Sciences and Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR), Kumasi, Ghana.
    Introduction: Buruli ulcer (BU) caused by Mycobacterium ulcerans is effectively treated with rifampicin and streptomycin for 8 weeks but some lesions take several months to heal. We have shown previously that some slowly healing lesions contain mycolactone suggesting continuing infection after antibiotic therapy. Now we have determined how rapidly combined M. Read More

    Environmental and Behavioral Drivers of Buruli Ulcer Disease in Selected Communities Along the Densu River Basin of Ghana: A Case-Control Study.
    Am J Trop Med Hyg 2017 May;96(5):1076-1083
    Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
    AbstractThe exact route of transmission of Mycobacterium ulcerans (MU) (causative agent of Buruli ulcer [BU]), risk factors, and reservoir hosts are not clearly known, although it has been identified as an environmental pathogen. This study assessed potential environmental and behavioral risk factors that influence BU infections. We conducted a case-control study where cases were matched by their demographic characteristics and place of residence. Read More

    Yaws resurgence in Bankim, Cameroon: The relative effectiveness of different means of detection in rural communities.
    PLoS Negl Trop Dis 2017 May 8;11(5):e0005557. Epub 2017 May 8.
    School of Anthropology, University of Arizona, Tucson, Arizona, United States of America.
    Background: Yaws is an infectious, debilitating and disfiguring disease of poverty that mainly affects children in rural communities in tropical areas. In Cameroon, mass-treatment campaigns carried out in the 1950s reduced yaws to such low levels that it was presumed the disease was eradicated. In 2010, an epidemiological study in Bankim Health District detected 29 cases of yaws. Read More

    Draft Genome Sequence of Mycobacterium ulcerans S4018 Isolated from a Patient with an Active Buruli Ulcer in Benin, Africa.
    Genome Announc 2017 Apr 27;5(17). Epub 2017 Apr 27.
    CRCINA, Inserm, CNRS, Université d'Angers, Université de Nantes, Nantes, France
    Currently, there are only two publicly available genomes of Mycobacterium ulcerans-the causative agent of the neglected, but devastating, tropical disease Buruli ulcer. Here, we report the draft genome sequence of isolate S4018, recovered from an active cutaneous lesion of a patient with Buruli ulcer in Benin, Africa. Read More

    Global and local environmental changes as drivers of Buruli ulcer emergence.
    Emerg Microbes Infect 2017 Apr 26;6(4):e22. Epub 2017 Apr 26.
    Institut de Recherche pour le Développement, Département Ecologie, Biodiversité et Fonctionnement des Ecosystemes Continentaux, UMR BOREA IRD 207, CNRS 7208, MNHN, UPMC, Muséum National d'Histoire Naturelle, 75231 Paris, France.
    Many emerging infectious diseases are caused by generalist pathogens that infect and transmit via multiple host species with multiple dissemination routes, thus confounding the understanding of pathogen transmission pathways from wildlife reservoirs to humans. The emergence of these pathogens in human populations has frequently been associated with global changes, such as socio-economic, climate or biodiversity modifications, by allowing generalist pathogens to invade and persist in new ecological niches, infect new host species, and thus change the nature of transmission pathways. Using the case of Buruli ulcer disease, we review how land-use changes, climatic patterns and biodiversity alterations contribute to disease emergence in many parts of the world. Read More

    Virulence potential of Staphylococcus aureus isolates from Buruli ulcer patients.
    Int J Med Microbiol 2017 Jun 19;307(4-5):223-232. Epub 2017 Apr 19.
    Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
    Buruli ulcer (BU) is a necrotizing infection of the skin and subcutaneous tissue caused by Mycobacterium ulcerans. BU wounds may also be colonized with other microorganisms including Staphylococcus aureus. This study aimed to characterize the virulence factors of S. Read More

    Disease ecology, health and the environment: a framework to account for ecological and socio-economic drivers in the control of neglected tropical diseases.
    Philos Trans R Soc Lond B Biol Sci 2017 Jun;372(1722)
    Department of Biology, Hopkins Marine Station, Stanford University, Pacific Grove, CA 93950, USA.
    Reducing the burden of neglected tropical diseases (NTDs) is one of the key strategic targets advanced by the Sustainable Development Goals. Despite the unprecedented effort deployed for NTD elimination in the past decade, their control, mainly through drug administration, remains particularly challenging: persistent poverty and repeated exposure to pathogens embedded in the environment limit the efficacy of strategies focused exclusively on human treatment or medical care. Here, we present a simple modelling framework to illustrate the relative role of ecological and socio-economic drivers of environmentally transmitted parasites and pathogens. Read More

    Landscape and environmental influences on Mycobacterium ulcerans distribution among aquatic sites in Ghana.
    PLoS One 2017 24;12(4):e0176375. Epub 2017 Apr 24.
    Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia, United States of America.
    Buruli ulcer, caused by Mycobacterium ulcerans, is highly endemic in West Africa. While the mode of transmission is unknown, many studies associate Buruli ulcer with different types of water exposure. We present results from the largest study to date to test for M. Read More

    Exposure Risk for Infection and Lack of Human-to-Human Transmission of Mycobacterium ulcerans Disease, Australia.
    Emerg Infect Dis 2017 May;23(5):837-840
    We conducted epidemiologic and genetic analyses of family clusters of Mycobacterium ulcerans (Buruli ulcer) disease in southeastern Australia. We found that the incidence of M. ulcerans disease in family members was increased. Read More

    Mycobacterium ulcerans low infectious dose and mechanical transmission support insect bites and puncturing injuries in the spread of Buruli ulcer.
    PLoS Negl Trop Dis 2017 Apr 14;11(4):e0005553. Epub 2017 Apr 14.
    Department of Microbiology and Immunology, at the Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Australia.
    Addressing the transmission enigma of the neglected disease Buruli ulcer (BU) is a World Health Organization priority. In Australia, we have observed an association between mosquitoes harboring the causative agent, Mycobacterium ulcerans, and BU. Here we tested a contaminated skin model of BU transmission by dipping the tails from healthy mice in cultures of the causative agent, Mycobacterium ulcerans. Read More

    In Vitro Susceptibility of Mycobacterium ulcerans Isolates to Selected Antimicrobials.
    Can J Infect Dis Med Microbiol 2017 14;2017:5180984. Epub 2017 Mar 14.
    Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana.
    Background. The current definitive treatment of Buruli ulcer with antibiotics makes the issue of antimicrobial drug resistance an unavoidable one. This is as a result of drug misuse by health personnel and patients' noncompliance to treatment regimen. Read More

    An Optimized Method for Extracting Bacterial RNA from Mouse Skin Tissue Colonized by Mycobacterium ulcerans.
    Front Microbiol 2017 24;8:512. Epub 2017 Mar 24.
    Center for Research in Cancerology and Immunology Nantes-Angers, Institut National de la Santé et de la Recherche Médicale, Université de Nantes, Université d'AngersAngers, France; Equipe Atip-Avenir, Center for Research in Cancerology and Immunology Nantes-Angers, Institut National de la Santé et de la Recherche Médicale, Centre Hospitalier Universitaire et Université d'AngersAngers, France.
    Bacterial transcriptome analyses during host colonization are essential to decipher the complexity of the relationship between the bacterium and its host. RNA sequencing (RNA-seq) is a promising approach providing valuable information about bacterial adaptation, the host response and, in some cases, mutual tolerance underlying crosstalk, as recently observed in the context of Mycobacterium ulcerans infection. Buruli ulcer is caused by M. Read More

    Chronic cutaneous mycobacterial ulcers due to Mycobacterium ulcerans (Buruli ulcer): the first indigenous case report from Jordan and a literature review.
    Int J Infect Dis 2017 May 23;58:77-81. Epub 2017 Mar 23.
    Internal Medicine Department, Jordan Hospital and Medical Center, Amman, Jordan.
    Background: Buruli ulcer is the third most common mycobacterial infection worldwide. It is endemic in tropical, subtropical, and temperate climates. It causes devastating disease with morbidity and mortality. Read More

    [Nontuberculous mycobacteria].
    Hautarzt 2017 May;68(5):403-411
    Klinik und Poliklinik für Dermatologie und Venerologie, Universität zu Köln, Kerpener Str. 62, 50937, Köln, Deutschland.
    Dermatologically relevant nontuberculous mycobacteria (NTM) include Mycobacterium marinum and Mycobacterium ulcerans and different rapidly growing mycobacteria (RGM). RGM are widely present in the environment and are facultative pathogenic. Diagnostic detection of nontuberculous mycobacteria is frequently challenging. Read More

    Experimental demonstration of the possible role of Acanthamoeba polyphaga in the infection and disease progression in Buruli Ulcer (BU) using ICR mice.
    PLoS One 2017 22;12(3):e0172843. Epub 2017 Mar 22.
    Department of Parasitology, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra, Ghana.
    The transmission of Buruli ulcer (BU), caused by Mycobacterium ulcerans (MU), remains puzzling although a number of hypothesis including through bites of infected aquatic insects have been proposed. We report the results of experiments using ICR mice that give credence to our hypothesis that Acanthamoeba species may play a role in BU transmission. We cocultured MU N2 and MU 1615 which expresses red fluorescent protein (RFP) and Acanthamoeba polyphaga (AP), and confirmed infected AP by Ziehl-Neelsen (ZN) staining. Read More

    Ecology and Feeding Habits Drive Infection of Water Bugs with Mycobacterium ulcerans.
    Ecohealth 2017 Jun 17;14(2):329-341. Epub 2017 Mar 17.
    UMR MIVEGEC IRD, CNRS, Université de Montpellier, Centre IRD de Montpellier, BP 64501, 34394, Montpellier Cedex, France.
    Mycobacterium ulcerans (MU), the causative agent of Buruli ulcer, is present in a wide spectrum of environments, including terrestrial and aquatic ecosystems in tropical regions. The most promising studies on the epidemiological risk of this disease suggest that some ecological settings may favor infection of animals with MU including human. A species' needs and impacts on resources and the environment, i. Read More

    The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR.
    ACS Chem Biol 2017 May 27;12(5):1297-1307. Epub 2017 Mar 27.
    Swiss Tropical and Public Health Institute , Socinstrasse 57, 4002 Basel, Switzerland.
    Mycolactone, the macrolide exotoxin produced by Mycobacterium ulcerans, is central to the pathogenesis of the chronic necrotizing skin disease Buruli ulcer (BU). Here we show that mycolactone acts as an inhibitor of the mechanistic Target of Rapamycin (mTOR) signaling pathway by interfering with the assembly of the two distinct mTOR protein complexes mTORC1 and mTORC2, which regulate different cellular processes. Inhibition of the assembly of the rictor containing mTORC2 complex by mycolactone prevents phosphorylation of the serine/threonine protein kinase Akt. Read More

    Genomic analysis of ST88 community-acquired methicillin resistant Staphylococcus aureus in Ghana.
    PeerJ 2017 28;5:e3047. Epub 2017 Feb 28.
    Department of Microbiology and Immunology, Doherty Applied Microbial Genomics, Doherty Institute for Infection and Immunity, University of Melbourne , Melbourne, VIC , Australia.
    Background: The emergence and evolution of community-acquired methicillin resistant Staphylococcus aureus (CA-MRSA) strains in Africa is poorly understood. However, one particular MRSA lineage called ST88, appears to be rapidly establishing itself as an "African" CA-MRSA clone. In this study, we employed whole genome sequencing to provide more information on the genetic background of ST88 CA-MRSA isolates from Ghana and to describe in detail ST88 CA-MRSA isolates in comparison with other MRSA lineages worldwide. Read More

    Assessing and managing wounds of Buruli ulcer patients at the primary and secondary health care levels in Ghana.
    PLoS Negl Trop Dis 2017 Feb 28;11(2):e0005331. Epub 2017 Feb 28.
    Section Clinical Tropical Medicine, Heidelberg University Hospital, Heidelberg, Germany.
    Background: Beyond Mycobacterium ulcerans-specific therapy, sound general wound management is required for successful management of Buruli ulcer (BU) patients which places them among the large and diverse group of patients in poor countries with a broken skin barrier.

    Methods: Clinically BU suspicious patients were enrolled between October 2013 and August 2015 at a primary health care (PHC) center and a municipal hospital, secondary health care (SHC) center in Ghana. All patients were IS2404 PCR tested and divided into IS2404 PCR positive and negative groups. Read More

    Cutaneous basidiobolomycosis: Seven cases in southern Benin.
    Ann Dermatol Venereol 2017 Apr 24;144(4):250-254. Epub 2017 Feb 24.
    Dermatology department, CNHU-HKM, faculté des sciences de la santé, BP 186, Cotonou, Benin.
    Background: Cutaneous basidiobolomycosis is the most common form of entomophthoramycosis. Herein we report seven cases of cutaneous basidiobolomycosis.

    Patients And Methods: A retrospective observational study was conducted at the Buruli ulcer treatment centre in Pobè and at the national teaching hospital in Cotonou from 2010 to 2015. Read More

    Analysis of Mycobacterium ulcerans-specific T-cell cytokines for diagnosis of Buruli ulcer disease and as potential indicator for disease progression.
    PLoS Negl Trop Dis 2017 Feb 27;11(2):e0005415. Epub 2017 Feb 27.
    Kumasi Centre for Collaborative Research in Tropical Medicine, KNUST, Kumasi, Ghana.
    Background: Buruli ulcer disease (BUD), caused by Mycobacterium (M.) ulcerans, is the third most common mycobacterial disease after tuberculosis and leprosy. BUD causes necrotic skin lesions and is a significant problem for health care in the affected countries. Read More

    Seasonal Pattern of Mycobacterium ulcerans, the Causative Agent of Buruli Ulcer, in the Environment in Ghana.
    Microb Ecol 2017 Aug 25;74(2):350-361. Epub 2017 Feb 25.
    Bacteriology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, P.O. Box LG 581, Legon, Accra, Ghana.
    This study aimed to contribute to the understanding of Mycobacterium ulcerans (MU) ecology by analysing both clinical and environmental samples collected from ten communities along two major river basins (Offin and Densu) associated with Buruli ulcer (BU) at different seasons. We collected clinical samples from presumptive BU cases and environmental samples from ten communities. Following DNA extraction, clinical samples were confirmed by IS2404 PCR and environmental samples were confirmed by targeting MU-specific genes, IS2404, IS2606 and the ketoreductase (KR) using real-time PCR. Read More

    Mycobacterium ulcerans mycolactone interferes with adhesion, migration and proliferation of primary human keratinocytes and HaCaT cell line.
    Arch Dermatol Res 2017 Apr 22;309(3):179-189. Epub 2017 Feb 22.
    Department of Translational Medicine, University of Piemonte Orientale "A. Avogadro", Via Solaroli 17, 28100, Novara, Italy.
    The pathogenicity of Mycobacterium ulcerans (Buruli ulcer) is closely associated with the secretion of exotoxin mycolactone. The cytotoxicity of mycolactone has been linked to its apoptogenic activity. We explored if low mycolactone concentrations, which are not able to induce apoptosis, can influence other essential activities on two primary human keratinocyte populations, keratinocyte stem cells (KSC) and transit amplifying cells (TAC), and on a human keratinocyte line, HaCaT. Read More

    Mycolactone reveals the substrate-driven complexity of Sec61-dependent transmembrane protein biogenesis.
    J Cell Sci 2017 Apr 20;130(7):1307-1320. Epub 2017 Feb 20.
    Division of Molecular and Cellular Function, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Michael Smith Building, Manchester M13 9PT, UK
    Mycolactone is the exotoxin virulence factor produced by Mycobacterium ulcerans, the pathogen responsible for Buruli ulcer. The skin lesions and immunosuppression that are characteristic of this disease result from the action of mycolactone, which targets the Sec61 complex and inhibits the co-translational translocation of secretory proteins into the endoplasmic reticulum. In this study, we investigate the effect of mycolactone on the Sec61-dependent biogenesis of different classes of transmembrane protein (TMP). Read More

    Molecular Characterization of Mycolactone Producing Mycobacteria from Aquatic Environments in Buruli Ulcer Non-Endemic Areas in Côte d'Ivoire.
    Int J Environ Res Public Health 2017 Feb 11;14(2). Epub 2017 Feb 11.
    Department of Environment and Health, Centre Suisse de Recherches Scientifiques en Côte d'Ivoire (CSRS), Adiopodoumé, 01 BP 1303, Abidjan 01, Côte d'Ivoire.
    Non-tuberculous mycobacteria (NTM), particularly mycolactone producing mycobacteria (MPM), are bacteria found in aquatic environments causing skin diseases in humans like Buruli ulcer (BU). Although the causative agent for BU, Mycobacterium ulcerans has been identified and associated with slow-moving water bodies, the real transmission route is still unknown. This study aimed to characterize MPMs from environmental aquatic samples collected in a BU non-endemic community, Adiopodoumé, in Côte d'Ivoire. Read More

    Design, synthesis, and cytotoxicity of stabilized mycolactone analogs.
    Bioorg Med Chem Lett 2017 Mar 17;27(5):1274-1277. Epub 2017 Jan 17.
    Department of Chemistry and Chemical Biology, Harvard University, 12 Oxford Street, Cambridge, MA 02138, USA. Electronic address:
    On exposure to visible light, mycolactone A/B, the causative toxin of Buruli ulcer, rearranges to a mixture of four photo-mycolactones apparently via a rare photochemically-induced [4πs+2πa] cycloaddition. In order to prevent the rearrangement, two C6'-C7' dihydromycolactone analogs 6'α-15 and 6'β-15 were designed and synthesized. 6'α-15 and 6'β-15 were shown to be stable under not only photochemical, but also acidic and basic conditions. Read More

    Outcome of Streptomycin-Rifampicin treatment of Buruli Ulcer in two Ghanaian districts.
    Pan Afr Med J 2016 1;25(Suppl 1):13. Epub 2016 Oct 1.
    Ghana Field Epidemiology and Laboratory Training programme, School of Public Health, University of Ghana.
    Introduction: Buruli ulcer (BU) is an infectious skin disease, caused by Mycobacterium ulcerans, endemic in more than 30 countries worldwide especially Africa. Brong-Ahafo Region implemented WHO recommended daily treatment with streptomycin and rifampicin for eight weeks (SR8). Yet limited assessment of therapy exists. Read More

    Multiple Introductions and Recent Spread of the Emerging Human Pathogen Mycobacterium ulcerans across Africa.
    Genome Biol Evol 2017 Mar;9(3):414-426
    Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
    Buruli ulcer (BU) is an insidious neglected tropical disease. Cases are reported around the world but the rural regions of West and Central Africa are most affected. How BU is transmitted and spreads has remained a mystery, even though the causative agent, Mycobacterium ulcerans, has been known for more than 70 years. Read More

    Effectiveness of purified methylene blue in an experimental model of Mycobacterium ulcerans infection.
    Int J Antimicrob Agents 2017 Mar 9;49(3):290-295. Epub 2017 Jan 9.
    Aix-Marseille Université, INSERM, CNRS, IRD, URMITE, Marseille, France. Electronic address:
    Mycobacterium ulcerans is responsible for Buruli ulcer, characterised by extensive, disabling ulcers. Standard treatment combining rifampicin and streptomycin exposes patients to toxicity and daily painful injections. In this study, the in vitro susceptibilities of 3 M. Read More


    High-Throughput Carbon Substrate Profiling of Mycobacterium ulcerans Suggests Potential Environmental Reservoirs.
    PLoS Negl Trop Dis 2017 Jan 17;11(1):e0005303. Epub 2017 Jan 17.
    Aix Marseille Univ, INSERM, CNRS, IRD, URMITE, Marseille, France.
    Background: Mycobacterium ulcerans is a close derivative of Mycobacterium marinum and the agent of Buruli ulcer in some tropical countries. Epidemiological and environmental studies pointed towards stagnant water ecosystems as potential sources of M. ulcerans, yet the ultimate reservoirs remain elusive. Read More

    Effectiveness of rifampicin-streptomycin for treatment of Buruli ulcer: a systematic review.
    JBI Database System Rev Implement Rep 2017 Jan;15(1):119-139
    1The Cameroon Centre for Evidence Based Health Care: a Joanna Briggs Institute Centre of Excellence, Yaounde, Cameroon, Africa 2Centre for Behavioral and Social Research, Yaounde, Cameroon, Africa 3Centre for Evidence Based Initiatives in Health Care: a Joanna Briggs Institute Centre of Excellence, University of Wollongong, Wollongong, New South Wales, Australia 4St George Hospital, Sydney, New South Wales, Australia.
    Background: Buruli ulcer (BU) disease is a chronic ulcerative skin disease caused by Mycobacterium ulcerans, which can lead to extensive destruction of the skin, soft tissues and occasionally of bones. Although several antibiotics have demonstrated bactericidal activity against M. ulcerans in vitro, no consensus on their clinical efficacy against M. Read More

    Phytotherapy against buruli ulcer in the Health District of Yamoussoukro (Cote d'Ivoire) : Identification, description, and symbolic functions of the plants and recipes used.
    Med Sante Trop 2016 Nov;26(4):408-413
    Centre suisse de recherches sentifiques en Côte d'Ivoire, 01 BP 1303 Abidjan 01, Côte d'Ivoire.
    This study aims to describe the plants and recipes proposed by traditional healers against Buruli ulcer in Côte d'Ivoire and to analyze their symbolic aspects. Buruli ulcer is an increasingly serious health problem in Côte d'Ivoire. The ivorian state through the National Buruli Ulcer Control Programme and its partners, has developed various actions to fight that disease. Read More

    Susceptibility Profiles of Mycobacterium ulcerans Isolates to Streptomycin and Rifampicin in Two Districts of the Eastern Region of Ghana.
    Int J Microbiol 2016 14;2016:8304524. Epub 2016 Dec 14.
    Department of Medical Microbiology, School of Biomedical and Allied Health Sciences, University of Ghana, Accra, Ghana.
    Background. Drug resistance is a major challenge in antibiotic chemotherapy. Assessing resistance profiles of pathogens constitutes an essential surveillance tool in the epidemiology and control of infectious diseases, including Buruli ulcer (BU) disease. Read More

    Epidemiology of Mansonella perstans in the middle belt of Ghana.
    Parasit Vectors 2017 Jan 7;10(1):15. Epub 2017 Jan 7.
    Department of Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
    Background: Mansonellosis was first reported in Ghana by Awadzi in the 1990s. Co-infections of Mansonella perstans have also been reported in a small cohort of patients with Buruli ulcer and their contacts. However, no study has assessed the exact prevalence of the disease in a larger study population. Read More

    Evaluating decontamination protocols for the isolation of Mycobacterium ulcerans from swabs.
    BMC Microbiol 2017 Jan 5;17(1). Epub 2017 Jan 5.
    Swiss Tropical Institute, Basel, Switzerland.
    Background: Mycobacterium ulcerans (M. ulcerans) is the causative agent of Buruli Ulcer (BU) disease. In order to inhibit the growth of the microbial contaminants during culture of M. Read More

    Antimycobacterial potency and cytotoxicity study of three medicinal plants.
    Int J Mycobacteriol 2016 Dec 27;5 Suppl 1:S206-S207. Epub 2016 Oct 27.
    Department of Clinical Pathology, Noguchi Memorial Institute for Medical Research, Accra, Ghana.
    Objective/background: Mycobacterial infections including tuberculosis, leprosy, and buruli ulcer are among the most prevalent, debilitating, and deadly tropical diseases, especially in Sub-Saharan Africa. The development of drug resistance to the currently available drugs and the poor compliance emphasize the need for new chemotherapeutic agents. This study was designed to evaluate the in vitro activity of Cleistopholis patens, Annona reticulata, and Greenwayodendron suaveolens against Mycobacterium smegmatis. Read More

    Antimycobacterial ingredients from plants used in traditional medicine to treat Buruli ulcer.
    Int J Mycobacteriol 2016 Dec 29;5 Suppl 1:S204-S205. Epub 2016 Nov 29.
    Department of Clinical Pathology, Noguchi Memorial Institute for Medical Research, Accra, Ghana; Department of Pharmacology and Toxicology, School of Pharmacy, University of Ghana, Accra, Ghana.
    Aim And Objectives: Buruli ulcer (BU) is a neglected tropical disease caused by a mycobacteria, Mycobacterium ulcerans. The WHO recommended Rifampicin-Streptomycin combination side effects and poor compliance, leaves rural populations with no choice than to patronise indigenous remedies. This study is aimed at validating medicinal plants used in traditional medicine to treat BU by investigating the in vitro efficacy and safety as well as their composition in active molecules. Read More

    Antimycobacterial activity of medicinal plants against the causative agent of buruli ulcer: Mycobacterium ulcerans.
    Int J Mycobacteriol 2016 Dec 23;5 Suppl 1:S105. Epub 2016 Nov 23.
    Antimicrobial and Biocontrol Agents Unit, Department of Biochemistry, Faculty of Science, University of Yaounde I, Yaounde, Cameroon.
    Objective/background: Buruli ulcer, known as necrotizing skin disease caused by Mycobacterium ulcerans, has emerged as the most prevalent mycobacteriosis after leprosy and tuberculosis. Accordingly, it has been classified by the World Health Organization as a neglected disease with high significance in tropical areas, including Cameroon. So far, the control of the disease relies mainly on the rifampin-streptomycin combination. Read More

    Characteristics and epidemiological profile of Buruli ulcer in the district of Tiassalé, south Côte d'Ivoire.
    Acta Trop 2016 Dec 27. Epub 2016 Dec 27.
    Unité de Formation et de Recherche des Sciences Médicales, Université Félix Houphouët-Boigny, 01 BP V 34, Abidjan 01, Côte d'Ivoire.
    Buruli ulcer (BU) is a cutaneous infectious disease caused by Mycobacterium ulcerans. It is the third most common mycobacterial disease in the world in the immunocompetent patient and second in Côte d'Ivoire after tuberculosis. This study aimed to assess the characteristics and epidemiological profile of BU in the district of Tiassalé, an important focus of the disease in south Côte d'Ivoire, in order to better direct actions for prevention and control. Read More

    Former Buruli Ulcer Patients' Experiences and Wishes May Serve as a Guide to Further Improve Buruli Ulcer Management.
    PLoS Negl Trop Dis 2016 Dec 29;10(12):e0005261. Epub 2016 Dec 29.
    University of Groningen, University Medical Center Groningen, Department of Internal Medicine/Infectious Diseases, Groningen, The Netherlands.
    Background: Buruli ulcer (BU), caused by Mycobacterium ulcerans, is a neglected tropical disease frequently leading to permanent disabilities. The ulcers are treated with rifampicin and streptomycin, wound care and, if necessary surgical intervention. Professionals have exclusively shaped the research agenda concerning management and control, while patients' perspective on priorities and preferences have not explicitly been explored or addressed. Read More

    Secondary bacterial isolates from previously untreated Buruli ulcer lesions and their antibiotic susceptibility patterns in Southern Nigeria.
    Rev Soc Bras Med Trop 2016 Nov-Dec;49(6):746-751
    Department of Medicine, Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria.
    Introduction:: Mycolactones, secreted by Mycobacterium ulcerans, were previously believed to prevent super infection in Buruli ulcer lesions. However, little is known about secondary bacterial infections in these lesions. This study evaluated contaminating bacterial flora and their antibiotic susceptibility patterns in cases of previously untreated Buruli ulcer disease from three states in Southern Nigeria. Read More

    Financial burden of health care for Buruli ulcer patients in Nigeria: the patients' perspective.
    Int Health 2017 Jan 15;9(1):36-43. Epub 2016 Dec 15.
    Department of Medicine, Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria
    Background: The economic burden of Buruli ulcer for patients has not been well-documented. This study assessed the costs of Buruli ulcer care to patients from the onset of illness to diagnosis and to the end of treatment.

    Methods: This was a cross-sectional cost of illness study conducted among patients with Buruli ulcer in four States in Nigeria between July and September 2015. Read More

    1 OF 18